NBP
NovaBridge Biosciences
1.40$
-2.1%
vs. previous close
Closing price · As of: Oct 7, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q1 20 | Q2 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q3 22 | Q1 23 | Q2 23 | Q3 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +0.0% | +106.0% | -52.8% | -27.8% | +0.0% | +100.0% | -99.5% | – | – | +23.2% | +0.0% | +295.2% | +0.0% | -26.2% | -627.2% | – | 0.0% | -410.3% | – | +6,207.8% | -100.0% | – | – | – | – | -100.0% | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | +0.0% | -41.3% | +0.0% | +100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +106.0% | -52.8% | -27.8% | +0.0% | +100.0% | -127.9% | – | – | +23.2% | +0.0% | +34.0% | +0.0% | +3.4% | -1,210.5% | – | 0.0% | -410.3% | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +10.4% | -0.4% | +18.9% | +0.0% | +136.4% | -29.4% | +100.7% | -42.3% | +15.7% | +0.0% | +4.5% | +0.0% | -27.0% | -0.1% | -1.3% | +0.0% | -79.7% | -14.1% | +181.0% | -95.9% | +34.7% | -87.1% | +323.9% | -3.6% | +1,652.5% | -87.1% | -0.3% | – | |
| – | +0.0% | +137.9% | +14.6% | +1,027.6% | +0.0% | -97.2% | +951.7% | +0.0% | +62.7% | +58.7% | +0.0% | +1.3% | +0.0% | -12.5% | +7.9% | -42.1% | +0.0% | -15.1% | -50.3% | +67.9% | -90.8% | -7.5% | -38.9% | -14.9% | +52.2% | +196.6% | -23.5% | -0.3% | – | |
| – | +0.0% | +7.1% | +24.6% | +155.5% | +0.0% | -24.7% | +80.3% | +6.2% | -35.8% | +32.0% | +0.0% | +2.3% | +0.0% | -20.9% | +3.6% | -21.0% | 0.0% | -56.8% | -39.3% | +116.5% | -93.7% | +7.7% | -60.6% | +35.1% | +26.4% | +711.0% | -72.1% | -0.3% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -89.1% | – | – | – | -1.4% | – | – | +20.3% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -20.4% | -148.1% | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | -94.7% | – | – | – | – | – | – | – | – | – | – | – | +0.0% | -100.0% | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | -4,505.3% | – | – | – | – | – | – | – | – | – | -258.5% | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | -153.6% | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 7, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.